Daily Morning Note – 21 May 2019


Register HERE for MONDAY’s 11.15am webinar.

Archived webinars available.


Asian stocks are set to decline Tuesday after U.S. tech stocks led a broad selloff. The fallout from the White House’s moves against Huawei reverberated, hitting some of the biggest component makers and fueling more trade angst. The dollar fell against most major currencies, with the Aussie pacing gains. Treasuries declined, with 10-year yields up more than two basis points. Oil rose, while gold was flat.

China warns about “unwavering resolve” to fight U.S. “bullying.” Asian equities are poised to follow U.S. stocks, which sank amid the Huawei fallout as tech shares got battered. And Ford is cutting back across the globe, eliminating 10% of its white-collar workforce.

China will retaliate after Trump blacklisted Huawei, Beijing’s ambassador to the EU said. “This is wrong behavior, so there will be a necessary response,” Zhang Ming told Bloomberg, describing the action as politically motivated. “The U.S. government is trying to bring down Huawei through administrative means.” Meanwhile, Nike, Adidas and other footwear giants urged Trump to reconsider his tariffs on shoes made in China.


SATS Ltd – Eyes set on growth abroad

Recommendation: Accumulate (Maintained), Last Done: S$5.08

Target Price: S$5.47, Analyst: Natalie Ong

– FY19 net income was in line with our expectations.

– Food Solutions and Gateway Services revenue grew 4.4% and 7.9% YoY, with growth
showing in both Aviation (+11.7%) and Non-Aviation (+8.8%) industries.

– Deepening presence in China through accretive acquisitions

– Food and cargo volumes at Brahims and PT CAS remain flat.

– Maintain ACCUMULATE; unchanged target price of $5.47.

Penguin International Ltd – Waddling is normal

Recommendation: BUY (Maintained), TP S$0.61

Last close: S$0.44, Analyst: Paul Chew

– Revenue is historically volatile and lumpy. No changes to our earnings forecast.

– Jump in inventories, non-financial liabilities and asset held for sale point to a healthy

– Balance sheet still in net cash position of S$43.8mn, or 45% of the market

– Our BUY recommendation and target price of S$0.61 remain unchanged.

China Everbright Water Ltd – On-Track expansion

Recommendation: BUY (Maintained), TP S$0.500

Last close: S$0.385, Analyst: Chen Guangzhi

– Both 1Q19 revenue and PATMI met our expectations.

– Two projects secured, 14 projects under construction and one project commenced
operation during 1Q19. Seven WWT projects hiked tariff in 1Q19

– 10% price difference between HK and SG market post-dual-listing

– We raise our target price to S$0.50 (previously SG$0.48) based on FY19e EPS of 5.5
SG cents and the slightly higher peers’ PER of 9.0x (previously 8.9x), and we
maintain our BUY recommendation.

SHS Holdings Ltd – Ceasing coverage

Analyst: Alvin Chia

– 1Q19 results missed our forecasts. The gestation period for the growth drivers were
much longer than expected.

– We are ceasing coverage on SHS Holdings Ltd. We had a NEUTRAL recommendation
with a TP of S$0.194. Our previous recommendation can no longer be relied on.

Read more research reports


US eases some restrictions on China’s Huawei to keep mobile networks operating. The US Commerce Department will allow Huawei Technologies to purchase American-made goods in order to maintain existing networks and provide software updates to existing Huawei handsets. The company is still prohibited from buying American parts and components to manufacture new products without license approvals that likely will be denied. The roll back, which is in effect for 90 days, suggests changes to Huawei’s supply chain may have immediate, far-reaching and unexpected consequences.

Oil touches multi-week highs as Opec signals it may extend cuts. US West Texas Intermediate crude futures rose 34 cents to settle at US$63.10 a barrel, after hitting US$63.81, the highest price since May 1. Brent crude futures fell 24 cents to settle at US$71.97 a barrel, having earlier touched US$73.40, their highest since April 26. Opec indicated it was likely to maintain production cuts that have helped boost prices this year, while escalating Middle East tensions provided further support.

2019 growth forecast for Singapore non-oil exports cut to -2 to 0%; fell 6.4% in Q1. Both the electronic and non-electronic NODX registered declines of 17.2 and 2.6 per cent respectively. The latest decline led Enterprise Singapore to revise down the projected NODX performance for the full year from 0 to 2 per cent growth to minus 2.0 to 0.0 per cent growth.

MTI downgrades Singapore’s 2019 economic growth forecast to 1.5-2.5% on weak outlook. This comes as the economy saw growth of 1.2 per cent in the first quarter of 2019, coming in a notch lower than earlier estimates of 1.3 per cent and revised figures from Q4 2018. This was also below economist expectations of 1.5 per cent. On a sequential basis, the Singapore economy expanded by 3.8 per cent, compared to the 0.8 per cent contraction in the preceding quarter.

Tianjin Zhongxin gets GMP certification for herbal medicinal slices. Anhui Medical Products Administration has recently awarded its wholly-owned subsidiary a certificate of good manufacturing practices (drug GMP certification) for its pharmaceutical products. The subsidiary, Tianjin Darentang (Bozhou) Chinese Herbal Medicinal Slices, develops, manufactures and sells traditional Chinese herbal medicinal slices.

Olam prices US$120m of notes in private placement. The wholly-owned subsidiary Olam Americas Inc (OAI) has successfully priced a US$120 million issuance of five-year fixed rate notes via a private placement. The notes were placed to nine investors at a fixed coupon of 3.89 per cent for five years. Proceeds from the notes issue will be used by OAI and its US affiliates for the repayment of existing debt and general corporate purposes.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR

Clients of Phillip Securities can keep updated with Country Strategy and Singapore Sector Reports by logging into: www.poems.com.sg > STOCKS > Research

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided “as is” without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com